{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:44:54Z","timestamp":1794638694366,"version":"4.9.1"},"reference-count":51,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["P01 NS097197"],"award-info":[{"award-number":["P01 NS097197"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS070899"],"award-info":[{"award-number":["R01 NS070899"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001605","name":"Epilepsy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012638","name":"Valerion Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012638","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Biospecimen Procurement and Translational Pathology Shared Resource Facility of the University of Kentucky Markey Cancer Center","award":["P30CA177558"],"award-info":[{"award-number":["P30CA177558"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lafora disease (LD) is a fatal juvenile epilepsy characterized by the accumulation of aberrant glucan aggregates called Lafora bodies (LBs). Delivery of protein-based therapeutics to the central nervous system (CNS) for the clearance of LBs remains a unique challenge in the field. Recently, a humanized antigen-binding fragment (hFab) derived from a murine systemic lupus erythematosus DNA autoantibody (3E10) has been shown to mediate cell penetration and proposed as a broadly applicable carrier to mediate cellular targeting and uptake. We report studies on the efficacy and CNS delivery of VAL-0417, an antibody\u2013enzyme fusion composed of the 3E10 hFab and human pancreatic \u03b1-amylase, in a mouse model of LD. An enzyme-linked immunosorbent assay has been developed to detect VAL-0417 post-treatment as a measure of delivery efficacy. We demonstrate the robust and sensitive detection of the fusion protein in multiple tissue types. Using this method, we measured biodistribution in different methods of delivery. We found that intracerebroventricular administration provided robust CNS delivery when compared to intrathecal administration. These data define critical steps in the translational pipeline of VAL-0417 for the treatment of LD.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.9b00396","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T15:16:45Z","timestamp":1563808605000},"page":"3791-3801","source":"Crossref","is-referenced-by-count":26,"title":["Central Nervous System Delivery and Biodistribution\nAnalysis of an Antibody\u2013Enzyme Fusion for the Treatment of\nLafora Disease"],"prefix":"10.1021","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9122-1022","authenticated-orcid":true,"given":"Grant\nL.","family":"Austin","sequence":"first","affiliation":[{"name":"University of Kentucky College of Medicine , , , ,","place":["Lexington, Kentucky, United States, 40536"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe R.","family":"Simmons","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Medicine , , , ,","place":["Lexington, Kentucky, United States, 40536"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Klier","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Medicine , , , ,","place":["Lexington, Kentucky, United States, 40536"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rondon","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Medicine , , , ,","place":["Lexington, Kentucky, United States, 40536"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad L.","family":"Hodges","sequence":"additional","affiliation":[{"name":"Valerion Therapeutics , , ,","place":["Concord, Massachusetts, United States, 01742"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Shaffer","sequence":"additional","affiliation":[{"name":"Valerion Therapeutics , , ,","place":["Concord, Massachusetts, United States, 01742"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine M.","family":"Aziz","sequence":"additional","affiliation":[{"name":"Valerion Therapeutics , , ,","place":["Concord, Massachusetts, United States, 01742"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy R.","family":"McKnight","sequence":"additional","affiliation":[{"name":"Valerion Therapeutics , , ,","place":["Concord, Massachusetts, United States, 01742"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Pauly","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Pharmacy , , , ,","place":["Lexington, Kentucky, United States, 40536"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin D.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Valerion Therapeutics , , ,","place":["Concord, Massachusetts, United States, 01742"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Vander Kooi","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Medicine , , , ,","place":["Lexington, Kentucky, United States, 40536"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5253-9049","authenticated-orcid":true,"given":"Matthew S.","family":"Gentry","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Medicine , , , ,","place":["Lexington, Kentucky, United States, 40536"]},{"name":"University of Kentucky College of Medicine , , , ,","place":["Lexington, Kentucky, United States, 40536"]},{"name":"University of Kentucky College of Medicine , , , ,","place":["Lexington, Kentucky, United States, 40536"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,7,22]]},"reference":[{"key":"2026081717212557000_cit1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tibs.2009.08.002","article-title":"Lafora Disease: Insights into Neurodegeneration\nfrom Plant Metabolism","volume":"34","author":"Gentry","year":"2009","journal-title":"Trends Biochem. Sci."},{"key":"2026081717212557000_cit2","doi-asserted-by":"publisher","first-page":"7117","DOI":"10.1074\/jbc.r117.803064","article-title":"Lafora\nDisease Offers a Unique Window into Neuronal Glycogen Metabolism","volume":"293","author":"Gentry","year":"2018","journal-title":"J. Biol. Chem."},{"key":"2026081717212557000_cit3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1684\/epd.2016.0842","article-title":"Lafora disease","volume":"18","author":"Turnbull","year":"2016","journal-title":"Epileptic Disord."},{"key":"2026081717212557000_cit4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1528-1157.1999.tb00893.x","article-title":"Idiopathic\nEpilepsies with a Complex Mode of Inheritance","volume":"40","author":"Serratosa","year":"1999","journal-title":"Epilepsia"},{"key":"2026081717212557000_cit5","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/hmg\/ddy044","article-title":"Astrocytes:\nNew Players\nin Progressive Myoclonus Epilepsy of Lafora Type","volume":"27","author":"Rubio-Villena","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"2026081717212557000_cit6","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1002\/glia.23463","article-title":"Astrocytes\nand Neurons Produce Distinct Types of Polyglucosan Bodies in Lafora\nDisease","volume":"66","author":"Auge\u0301","year":"2018","journal-title":"Glia"},{"key":"2026081717212557000_cit7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1742-4658.2012.08549.x","article-title":"Laforin, a Protein with Many Faces:\nGlucan Phosphatase, Adapter Protein, et Alii","volume":"280","author":"Gentry","year":"2013","journal-title":"FEBS J."},{"key":"2026081717212557000_cit8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.molcel.2014.11.020","article-title":"Structural\nMechanism of Laforin Function in Glycogen Dephosphorylation\nand Lafora Disease","volume":"57","author":"Raththagala","year":"2015","journal-title":"Mol. Cell"},{"key":"2026081717212557000_cit9","doi-asserted-by":"publisher","first-page":"23361","DOI":"10.1074\/jbc.m115.658203","article-title":"Mechanistic\nInsights into Glucan Phosphatase Activity against Polyglucan Substrates","volume":"290","author":"Meekins","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2026081717212557000_cit10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/archneur.1965.00460260062008","article-title":"Lafora\u2019s Disease","volume":"12","author":"Schwarz","year":"1965","journal-title":"Arch.\nNeurol."},{"key":"2026081717212557000_cit11","first-page":"125","article-title":"Isolation\nand characterization of\nLafora bodies in two cases of myoclonus epilepsy","volume":"26","author":"Yokoi","year":"1967","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2026081717212557000_cit12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/nn1998","article-title":"Mechanism Suppressing Glycogen Synthesis in Neurons and Its Demise\nin Progressive Myoclonus Epilepsy","volume":"10","author":"Vilchez","year":"2007","journal-title":"Nat. Neurosci."},{"key":"2026081717212557000_cit13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/jcbfm.2014.33","article-title":"Neurons Have an Active Glycogen Metabolism That Contributes\nto Tolerance to Hypoxia","volume":"34","author":"Saez","year":"2014","journal-title":"J. Cereb. Blood Flow\nMetab."},{"key":"2026081717212557000_cit14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/hmg\/11.11.1251","article-title":"Targeted Disruption of the Epm2a Gene Causes Formation\nof Lafora Inclusion Bodies, Neurodegeneration, Ataxia, Myoclonus Epilepsy\nand Impaired Behavioral Response in Mice","volume":"11","author":"Ganesh","year":"2002","journal-title":"Hum.\nMol. Genet."},{"key":"2026081717212557000_cit15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002037","article-title":"PTG Depletion Removes Lafora Bodies and Rescues\nthe Fatal Epilepsy of Lafora Disease","volume":"7","author":"Turnbull","year":"2011","journal-title":"PLoS Genet."},{"key":"2026081717212557000_cit16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ana.24104","article-title":"PTG protein\ndepletion rescues malin-deficient Lafora disease in mouse","volume":"75","author":"Turnbull","year":"2014","journal-title":"Ann. Neurol."},{"key":"2026081717212557000_cit17","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen Accumulation Underlies Neurodegeneration\nand\nAutophagy Impairment in Lafora Disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum.\nMol. Genet."},{"key":"2026081717212557000_cit18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.yebeh.2017.12.015","article-title":"The 3rd International\nLafora Epilepsy Workshop: Evidence\nfor a Cure","volume":"81","author":"Brewer","year":"2018","journal-title":"Epilepsy Behav."},{"key":"2026081717212557000_cit19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.yebeh.2018.11.014","article-title":"The 4th International Lafora Epilepsy\nWorkshop: Shifting\nParadigms, Paths to Treatment, and Hope for Patients","volume":"90","author":"Brewer","year":"2019","journal-title":"Epilepsy Behav."},{"key":"2026081717212557000_cit20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion\nProtein Linkers: Property,\nDesign and Functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2026081717212557000_cit21","doi-asserted-by":"publisher","first-page":"S314","DOI":"10.1016\/j.jaci.2009.08.018","article-title":"Immunomodulator\nTherapy: Monoclonal\nAntibodies, Fusion Proteins, Cytokines, and Immunoglobulins","volume":"125","author":"Lee","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026081717212557000_cit22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1100\/tsw.2005.98","article-title":"Antibody\nMediated Transduction of\nTherapeutic Proteins into Living Cells","volume":"5","author":"Hansen","year":"2005","journal-title":"Sci.\nWorld J."},{"key":"2026081717212557000_cit23","doi-asserted-by":"publisher","first-page":"20790","DOI":"10.1074\/jbc.c700090200","article-title":"Intranuclear Protein\nTransduction through a Nucleoside\nSalvage Pathway","volume":"282","author":"Hansen","year":"2007","journal-title":"J. Biol. Chem."},{"key":"2026081717212557000_cit24","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.3760\/cma.j.issn.1005-1201.2017.07.022","article-title":"Mechanisms\nof Cellular Penetration and Nuclear Localization of an Anti-Double\nStrand DNA Autoantibody","volume":"157","author":"Zack","year":"1996","journal-title":"J. Immunol."},{"key":"2026081717212557000_cit25","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/hmg\/ddt003","article-title":"Enzyme replacement therapy rescues weakness\nand improves muscle pathology in mice with X-linked myotubular myopathy","volume":"22","author":"Lawlor","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"2026081717212557000_cit26","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1158\/1535-7163.mct-12-0476-t","article-title":"A Cell-Penetrating\nBispecific Antibody for Therapeutic Regulation of Intracellular Targets","volume":"11","author":"Weisbart","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"2026081717212557000_cit27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","article-title":"Antibody-Mediated Enzyme Replacement\nTherapy Targeting Both Lysosomal and Cytoplasmic Glycogen in Pompe\nDisease","volume":"95","author":"Yi","year":"2017","journal-title":"J. Mol. Med."},{"key":"2026081717212557000_cit28","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.ymgme.2018.12.211","article-title":"Safety and Efficacy of VAL-1221,\na Novel Fusion Protein Targeting\nCytoplasmic Glycogen, in Patients with Late-Onset Pompe Disease","volume":"126","author":"Kishnani","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"2026081717212557000_cit29","doi-asserted-by":"publisher","first-page":"157ra142","DOI":"10.1126\/scitranslmed.3004385","article-title":"Targeting Cancer with a Lupus Autoantibody","volume":"4","author":"Hansen","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"2026081717212557000_cit30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1006\/jaut.1998.0212","article-title":"An Autoantibody\nIs Modified for Use as a Delivery System to Target the Cell Nucleus:\nTherapeutic Implications","volume":"11","author":"Weisbart","year":"1998","journal-title":"J. Autoimmun."},{"key":"2026081717212557000_cit31","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.4049\/jimmunol.164.11.6020","article-title":"Novel Protein\nTransfection of Primary Rat Cortical Neurons Using an Antibody That\nPenetrates Living Cells","volume":"164","author":"Weisbart","year":"2000","journal-title":"J. Immunol."},{"key":"2026081717212557000_cit32","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1124\/dmd.104.001123","article-title":"Tissue Distribution\nof Concentrative\nand Equilibrative Nucleoside Transporters in Male and Female Rats\nand Mice","volume":"32","author":"Lu","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"2026081717212557000_cit33","first-page":"2602","article-title":"Idiotypic\nvaccination\nwith a murine anti-dsDNA antibody: phase I study in patients with\nnonactive systemic lupus erythematosus with nephritis","volume":"26","author":"Spertini","year":"1999","journal-title":"J. Rheumatol."},{"key":"2026081717212557000_cit34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/19.6.382","article-title":"Studies in Myoclonus Epilepsy III.\nThe Effects of Amylolytic Enzymes on the Ultrastructure of Lafora\nBodies","volume":"19","author":"Nikaido","year":"1971","journal-title":"J. Histochem. Cytochem."},{"key":"2026081717212557000_cit35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.07.002","article-title":"Targeting Pathogenic\nLafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion","author":"Brewer","year":"2019","journal-title":"Cell Metabolism"},{"key":"2026081717212557000_cit36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1001\/archneur.1968.00480010033002","article-title":"Studies in Myoclonus\nEpilepsy (Lafora Body Form)","volume":"19","author":"Yokoi","year":"1968","journal-title":"Arch. Neurol."},{"key":"2026081717212557000_cit37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/bf01677415","article-title":"Meine Methode\nder quantitativen Analyse des Glykogenes und die Arteigenthu\u0308mlichkeit\nder Substanzen des Thierleibes","volume":"129","author":"Pflu\u0308ger","year":"1909","journal-title":"Pflugers Arch.\nfu\u0308r Gesamte Physiol. Menschen Tiere"},{"key":"2026081717212557000_cit38","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.4049\/jimmunol.144.7.2653","article-title":"A Conserved Anti-DNA Antibody Idiotype Associated with\nNephritis in Murine and Human Systemic Lupus Erythematosus","volume":"144","author":"Weisbart","year":"1990","journal-title":"J. Immunol."},{"key":"2026081717212557000_cit39","volume-title":"Assay Guidance Manual","author":"Sittampalam","year":"2017"},{"key":"2026081717212557000_cit40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ab.2017.10.025","article-title":"An ELISA Method to Estimate the Mono ADP-Ribosyltransferase\nActivities: E.g in Pertussis Toxin and Vaccines","volume":"540\u2013541","author":"Asokanathan","year":"2018","journal-title":"Anal. Biochem."},{"key":"2026081717212557000_cit41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ab.2013.02.024","article-title":"Use of Whole\nBlood for Analysis of Disease-Associated Biomarkers","volume":"437","author":"May","year":"2013","journal-title":"Anal. Biochem."},{"key":"2026081717212557000_cit42","first-page":"382","article-title":"Lafora Disease a Form of Progressive Myoclonus Epilepsy","volume-title":"The Epilepsies. Handbook of Clinical Neurology","author":"Van Heycop Ten","year":"1975"},{"key":"2026081717212557000_cit43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2016.10.022","article-title":"Intracerebroventricular Delivery\nas a Safe, Long-Term Route of Drug Administration","volume":"67","author":"Cohen-pfeffer","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"2026081717212557000_cit44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ymgme.2018.05.003","article-title":"Best Practices\nfor the Use of Intracerebroventricular Drug Delivery Devices","volume":"124","author":"Slavc","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"2026081717212557000_cit45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.clim.2018.09.003","article-title":"Immunogenicity to Cerliponase Alfa Intracerebroventricular\nEnzyme Replacement Therapy for CLN2 Disease: Results from a Phase\n1\/2 Study","volume":"197","author":"Cherukuri","year":"2018","journal-title":"Clin. Immunol."},{"key":"2026081717212557000_cit46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","article-title":"Therapeutic Landscape for Batten\nDisease: Current Treatments and Future Prospects","volume":"15","author":"Johnson","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"2026081717212557000_cit47","unstructured":"Watts, R. J.; Zuchero, J. Y.; Crouch, J.; Dennis, M.\n          Methods for Improving\nSafety of Blood-Brain Barrier Transport. EP 2852618A2, Jan 31, 2019."},{"key":"2026081717212557000_cit48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2014.10.034","article-title":"Probing the Extracellular Diffusion\nof Antibodies in Brain Using in Vivo Integrative Optical Imaging and\nEx Vivo Fluorescence Imaging","volume":"197","author":"Wolak","year":"2015","journal-title":"J. Control. Release"},{"key":"2026081717212557000_cit49","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1113\/jp275105","article-title":"Intrathecal Antibody Distribution in the\nRat Brain: Surface Diffusion, Perivascular Transport and Osmotic Enhancement\nof Delivery","volume":"596","author":"Pizzo","year":"2018","journal-title":"J. Physiol."},{"key":"2026081717212557000_cit50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00401-018-1812-4","article-title":"The role\nof brain barriers in fluid movement in the CNS: is there a \u201cglymphatic\u201d\nsystem?","volume":"135","author":"Abbott","year":"2018","journal-title":"Acta Neuropathol."},{"key":"2026081717212557000_cit51","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1021\/acs.bioconjchem.8b00548","article-title":"Passive Immunotherapies for Central\nNervous System Disorders: Current Delivery Challenges and New Approaches","volume":"29","author":"Kumar","year":"2018","journal-title":"Bioconjug. Chem."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.9b00396","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/16\/9\/3791\/13584412\/mp9b00396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/16\/9\/3791\/13584412\/mp9b00396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:39:41Z","timestamp":1787002781000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/16\/9\/3791\/507330\/Central-Nervous-System-Delivery-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,22]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,7,22]]},"published-print":{"date-parts":[[2019,9,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00396","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/671214","asserted-by":"object"}],"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00396.s001","asserted-by":"subject"}]},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,22]]}}}